睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由河北医科大学第四医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07635342,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 65 岁;性别:仅女性

    登记记录的入选字段

  2. Patients with previously untreated invasive breast cancer confirmed by pathological examination.

    入选标准第 2 条

    HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status.

    入选标准第 3 条

  3. Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.

    入选标准第 4 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 6 条

  5. Hemoglobin ≥100 g/L.

    入选标准第 8 条

    Absolute neutrophil count ≥1.5 × 10\^9/L.

    入选标准第 9 条

    Platelet count ≥100 × 10\^9/L.

    入选标准第 10 条

    Total bilirubin ≤1 × upper limit of normal (ULN).

    入选标准第 11 条

    Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN.

    入选标准第 12 条

    Alkaline phosphatase ≤2.5 × ULN.

    入选标准第 13 条

    Blood urea nitrogen and serum creatinine ≤1.5 × ULN.

    入选标准第 14 条

  6. At least one measurable lesion according to RECIST version 1.1.

    入选标准第 5 条

  7. Breast cancer not confirmed by pathological examination.

    排除标准第 5 条

    History of other malignancies within 5 years, except cured carcinoma in situ of the cervix.

    排除标准第 6 条

    History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.

    排除标准第 11 条

  8. Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07635342,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female patients aged 18 to 65 years.
  2. Patients with previously untreated invasive breast cancer confirmed by pathological examination.
  3. HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status.
  4. Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
  5. At least one measurable lesion according to RECIST version 1.1.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  7. Adequate organ function, meeting all of the following criteria:
  8. Hemoglobin ≥100 g/L.
  9. Absolute neutrophil count ≥1.5 × 10\^9/L.
  10. Platelet count ≥100 × 10\^9/L.
  11. Total bilirubin ≤1 × upper limit of normal (ULN).
  12. Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN.
  13. Alkaline phosphatase ≤2.5 × ULN.
  14. Blood urea nitrogen and serum creatinine ≤1.5 × ULN.
  15. Left ventricular ejection fraction ≥55% by echocardiography.
  16. Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the study and for 8 weeks after the last dose of study treatment.
  17. Patients must voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.

排除标准:Exclusion Criteria:

  1. Prior receipt of any anti-tumor therapy, including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy.
  2. Concurrent receipt of any other anti-tumor therapy.
  3. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
  4. Stage IV breast cancer.
  5. Breast cancer not confirmed by pathological examination.
  6. History of other malignancies within 5 years, except cured carcinoma in situ of the cervix.
  7. Severe dysfunction of major organs, including the heart, liver, or kidney.
  8. Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that may affect drug administration or absorption.
  9. Participation in another drug clinical trial within 4 weeks before enrollment.
  10. Known history of allergy to any component of the study treatment.
  11. History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
  12. History of any cardiac disease, including clinically significant arrhythmia requiring medication, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to make the patient unsuitable for this study.
  13. Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study.
  14. Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or affect completion of the study, including but not limited to uncontrolled severe hypertension, severe diabetes mellitus, or active infection.
  15. Clear history of neurological or psychiatric disorders, including epilepsy or dementia.
  16. Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07635342, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07635342,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07635342